Sai Parenteral's (NSE:SAIPARENT) Earnings Power Value (EPV): ₹-42.70 (As of Mar25)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAIPARENT Sai Parenteral's Ltd NSE:SAIPARENT
14 GF Score
Price ₹569.70
! 7 Warning Signs
View Full Analysis

What is Sai Parenteral's Earnings Power Value (EPV)?

Sai Parenteral's NSE:SAIPARENT +5.28% 14 Earnings Power Value (EPV) is ₹-42.70 as of Mar25. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review.

As of Mar25, Sai Parenteral's's earnings power value is ₹-42.70. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Sai Parenteral's  (NSE:SAIPARENT) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Sai Parenteral's Earnings Power Value (EPV) Related Terms


Sai Parenteral's Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Sai Parenteral's's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Parenteral's Earnings Power Value (EPV) Chart

Sai Parenteral's Annual Data
Trend Mar23 Mar24 Mar25
Earnings Power Value (EPV)
0.00 0.00 0.00

Sai Parenteral's Semi-Annual Data
Mar23 Mar24 Mar25 Sep25
Earnings Power Value (EPV) 0.00 0.00 0.00 0.00

NSE:SAIPARENT vs LLY, JNJ, ABBV: Earnings Power Value (EPV) Comparison

For the Drug Manufacturers - General subindustry, Sai Parenteral's's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sai Parenteral's Earnings Power Value (EPV) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Sai Parenteral's's Earnings Power Value (EPV) falls into.


NSE:SAIPARENT
14GF Score
Sai Parenteral's Ltd NSE:SAIPARENT
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Parenteral's Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

What does a Earnings Power Value (EPV) of ₹-42.70 mean?
Sai Parenteral's (NSE:SAIPARENT) has a Earnings Power Value (EPV) of ₹-42.70 as of Mar25. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Sai Parenteral's and its competitors.
Is Sai Parenteral's' Earnings Power Value (EPV) too high?
Sai Parenteral's' current Earnings Power Value (EPV) is ₹-42.70. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Earnings Power Value (EPV) compare to LLY and JNJ?
Sai Parenteral's' Earnings Power Value (EPV) of ₹-42.70 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Drug Manufacturers company?
A good Earnings Power Value (EPV) depends on the Drug Manufacturers industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Sai Parenteral's and its competitors. Sai Parenteral's's current Earnings Power Value (EPV) is ₹-42.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Earnings Power Value (EPV) of ₹-42.70. The current Earnings Power Value (EPV) is ₹-42.70. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Earnings Power Value (EPV) is ₹-42.70 as of Mar25. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Parenteral's Business Description

Other Exchanges 544742:India
Address Plot No 39, 5th floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, TG, IND, 500032
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score

Get the complete analysis for NSE:SAIPARENT

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹569.70
Price